Biotech firm ValiRx has appointed a Chief Operating Officer to assist in building and adding value to its portfolio of technologies and to coordinate ValiRx's commercial strategy.
Samual Ogunsalu has a background in Microbiology and Biochemical engineering and has 15 years' experience in the identification and commercialisation of early and mid-stage life-science opportunities and in the out-licensing of portfolio technologies.
He has previously held positions as the Head of Commercialisation and the sector specialist for Life-Sciences at the Knowledge East Partnership, as well as the Principle Executive of Commercial Development at Queen Mary Innovation, the technology development and innovation company, out of Queen Mary College, University of London.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Dr Satu Vainikka, the group's Chief Executive Officer, said: "I am delighted to be working with Sam again, this time under the ValiRx umbrella and I look forward to benefitting from his past experience, contacts and intimate understanding of the challenges associated with the commercialisation and further development of companies and technologies in our space.
"ValiRx is now ready to change gear and Sam will help us to exploit value in our IP portfolio and prepare the group for out-licensing partnerships and taking ValiRx to the next stage."
The share price rose 1.77% to 0.57p by 13:25.
NR
